Introduction
Human herpesvirus 6 (HHV-6) is a T-cell tropic virus that was detected in various AIDS-related and other human lymphoid malignancies. First isolated from patients with lymphoproliferative disorders and AIDS, HHV-6 was proposed as a co-factor in the progression of AIDS (Ablashi et al., 1987 Lusso et al., 1988; Lusso et al., 1995; Takahashi et al., 1989) . HHV-6 infection causes exanthem subitum (Yamanishi et al., 1988) and has been linked to meningoencephalitis (Ishiguro et al., 1990) , infectious mononucleosis (Steeper et al., 1990; Bertram et al., 1991) , persistent lymphadenopathy (Niederman et al., 1988) , fulminant hepatitis with atypical lymphocytosis and lymphadenopathy (Asano et al., 1990) , autoimmune disorders , chronic fatigue syndrome (Buchwald et al., 1992) , Kikuchi syndrome, a form of necrotizing lymphadenopathy (Kikuchi et al., 1992) , pneumonitis (Carrigan et al., 1991) , and multiple sclerosis (Challoner et al., 1995) . HHV-6 was also detected by in situ hybridization in Rosai ± Dorfman disease, a form of massive, generally benign lymphadenopathy aecting children and young adults (Levine et al., 1992) . HHV-6 isolates are grouped into variants A and B and have been detected in saliva and peripheral blood leukocytes (PBL) of healthy adults (Cone et al., 1993) and in PBLs of children with exanthem subitum . For a review, see Pellett and Black (1996) . Speci®c HHV-6 restriction enzyme fragments that exhibited transforming potential have been identi®ed. ZVH14 and ZVB70 fragments, isolated from variant A strain GS, transformed rodent cells (Razzaque, 1990) . Moreover, ZVH14 and ZVB70 converted non-tumorigenic SV40/adenovirus-immortalized human epidermal keratinocytes to a malignant phenotype (Razzaque et al., 1993) . The tumorigenic potential of the SalI-L fragment from variant A strain U1102, was described by our laboratory. SalI-L transformed both primary and established rodent cells , and in contrast to ZVH14 and ZVB70, was retained in focally transformed and tumor-derived lines as assessed by Southern blot analysis. Sequence analysis of SalI-L indicated seven open reading frames (ORFs), one of which, ORF-1, exhibited up-regulation of the HIV-1 LTR promoter leading to increased HIV-1 expression and viral production .
In the current study, the transforming activity of SalI-L was localized to the SalI-L-SH subfragment and then to ORF-1 (also designated DR7 (Gompels et al., 1995; Nicholas, 1996) ). Cells expressing ORF-1 protein were tumorigenic when injected into nude mice, while cells expressing truncated ORF-1 protein (after residue 172) were not. Furthermore, ORF-1 protein bound to the speci®c DNA binding domain of p53. ORF-1 also inhibited p53-activated transcription while the truncated ORF-1 mutant did not. Moreover, ORF-1 RNA and protein were expressed in HHV-6 infected cells at 18 h post-infection, indicating that ORF-1 is a viral gene product. PCR analysis of human tumors detected ORF-1 sequences in the lymph nodes of ®ve of 12 patients with angioimmunoblastic lymphadenopathy, as well as in Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) and glioblastoma at a lower frequency.
Results
Sequence analysis of SalI-L revealed seven ORFs ranging in size from 90 to 357 aa ( Figure 1a ); three were on one strand and four on the other. To de®ne the minimal transforming region, a series of six subclones of SalI-L that exhibit progressive 5' and/or 3' deletions were constructed (Figure 1b) . These subclones were co-transfected with a pCHC6 plasmid carrying a hygromycin resistance marker under control of the HCMV immediate-early promoter. Hygromycin resistant colonies derived from each transfection were pooled and sub-cultured for focus assays. Only cultures derived from co-transfection with intact SalI-L or SalI-L-SH exhibited transformed foci, indicating that SalI-L-SH contains the minimal transforming region.
To identify which ORF was responsible for transforming ability, ORFs 71, 73 and 77 (all within SalI-L-SH) were PCR ampli®ed, sequenced and subcloned in the sense orientation into pBK-CMV (Stratagene Cloning Systems), a mammalian expression vector carrying the human cytomegalovirus (HCMV) immediate early promoter and the selectable marker for neomycin resistance. Next, each pBK/ORF Figure 1 Localization of the SalI-L transforming region to SalI-L-SH. (a) SalI restriction map of HHV-6 variant A strain U1102 is shown with the location and size of the open reading frames within the L fragment . The gray ®lled rectangle within the SalI-L fragment represents the junctional telomeric repeats ([TAACCC] 43 ) which divide the direct repeat left (DR L ) from the unique segment. The vertical arrow indicates the position of insertion of the translation termination linker used to mutate ORF-1. (b) Transforming ability of SalI-L subfragments. NIH3T3 cells were co-transfected with SalI-L subfragment constructs and pCHC6. Hygromycin resistant cells were analysed for focus forming ability, i.e. morphologic transformation ORF-1 oncoprotein binds to and inhibits p53 F Kashanchi et al construct was transfected into NIH3T3 cells and cultures were monitored for the development of morphologically transformed foci. At 5 weeks posttransfection, 16 foci per dish were observed for cells transfected with pBK/ORF1, whereas only background levels of less than three foci per dish were obtained with pBK-CMV, pBK/ORF3, or pBK/ORF7. To insure that the foci arose from transfected cells rather than from spontaneous transformants, the foci were placed under geneticin (neomycin) selection. Only foci from the pBK/ORF1 transfected cell cultures survived geneticin selection. The oncogenic potential of ORF-1 was examined next. To insure that ORF-1 translation was required for transformation, mutant plasmid, pBK/ORF1-TTL 172 , was constructed. A translation termination linker (TTL) was inserted after residue 172 of ORF-1 upstream of ORF-3, leaving the latter intact ( Figure  1 ). pBK/ORF1, pBK/ORF1-TTL 172 , and pBK-CMV (parental vector) were transfected into NIH3T3 cells. Resistant colonies grew after geneticin selection of cells transfected with each of the three plasmids. However, morphologically transformed colonies were (Liu et al., 1993 (Liu et al., , 1994 Mansur et al., 1995; Wang et al., 1993 Wang et al., , 1994 Ruppert and Stillman, 1993) , and 5' and 3' truncated proteins tested for binding to ORF-1. The numbered rectangles designate evolutionally conserved domains (Soussi et al., 1990) . (c) Percent of wild type and truncated p53 proteins bound to unlabeled ORF-1 after immunoprecipitation with anti-ORF1 antibody ORF-1 oncoprotein binds to and inhibits p53 F Kashanchi et al observed only with pBK/ORF1 and not with pBK/ ORF1-TTL 172 or pBK-CMV (data not shown). Extracts from 3T3-pBK-1, 3T3-ORF1-1 and 3T3-ORF1/TTL 172 -1 cells were prepared and Western blotted with anti-ORF-1 polyclonal rabbit sera, raised from puri®ed ORF-1 protein isolated from bacteria . Wild type ORF-1 protein and the C-terminal truncated protein expressed from the TTL 172 construct were observed in the appropriate cells ( Figure 2a , lanes 2 and 3, respectively). These cells were next injected into nude mice. Nine of nine mice injected with 3T3-ORF1-1 cells expressing wild type ORF-1 protein developed tumors within 3 to 4 weeks, while 0 of 10 mice injected with 3T3-ORF1/ TTL 172 -1 cells expressing truncated ORF-1 cells and 1 of nine mice (at 6 weeks) injected with 3T3-pBK-1 cells developed tumors.
At 5 to 6 weeks post-injection, animals were sacri®ced and the tumors were analysed for both histology and the expression of ORF-1. The tumors were classi®ed as ®brosarcomas ( Figure 2b ) as previously observed for tumors resulting from innoculation of mice with SalI-L transformed cells . ORF-1 protein was detected in both tissues ( Figure 2c ) and cell lines (data not shown) derived from the tumors.
The expression of ORF-1 protein in transformed cells and tumor tissues suggested a maintenance function of ORF-1 in neoplastic transformation. Because binding to tumor suppressor protein p53 is characteristic of several viral oncoproteins (Levine, 1993; Huibregtse et al., 1994) , ORF-1 was tested for binding to p53. In preliminary studies employing GST pull down assays, ORF-1 was observed to bind to GST/p53 but not to GST alone (data not shown). In co-immunoprecipitation assays, anti-ORF-1 serum precipitated the p53/ORF-1 complex ( Figure 3a) . No precipitation of p53 was observed in experiments using either p53 alone with anti-ORF-1 serum or p53 plus ORF-1 with preimmune serum. These results demonstrated speci®c binding between ORF-1 and p53. Next, immunoprecipitation experiments were performed with truncated p53 proteins, 3R, 4U, and D11 ( Figure 3b ). ORF-1 bound to the 3R and D11 mutants, but not to 4U (Figure 3c ). The results indicate that the ORF-1 binding domain of p53 is between residues 28 and 187 with a critical region between 107 and 187.
Because the ORF-1 and speci®c DNA binding domains of p53 overlapped, the ability of ORF-1 to aect p53-activated transcription was examined. 3T3-ORF-1, 3T3-ORF1/TTL 172 -1, and NIH3T3 cells were transfected with p53G5BCAT, a p53 responsive reporter construct, containing p53 binding sites upstream of the CAT gene ( Figure 4 ). Upon transfection of NIH3T3 cells with p53G5BCAT, tenfold greater CAT activity was observed compared to transfection with pCAT-Basic which contained no p53 binding sites. However, when p53G5BCAT was transfected into 3T3-ORF1-1 cells, an eightfold decrease in CAT activity was observed compared to transfection into NIH3T3 cells. This decrease in CAT activity did not occur in cells expressing the TTL 172 truncated ORF-1 protein, demonstrating that the suppression of p53-activated transcription was speci®c to ORF-1. Moreover, the level of p53 as determined by Western blot analysis was similar in 3T3-ORF1-1, 3T3-ORF1/ TTL 172 -1, and NIH3T3 cells (data not shown). Finally, CAT activity was similar in NIH3T3, 3T3-ORF1-1, and 3T3-ORF1/TTL 172 -1 cells after transfection with pSV2CAT which contained no p53 binding sites (data not shown). This demonstrated the 2 3 4 5 6 7 8 9
Figure 5 ORF-1 mRNA and protein expression in HHV-6 infected cells. At indicated times post-infection, infected cell samples were taken for RNA and protein isolation. (a) RT ± PCR analysis. PCR products were electrophoretically separated in a 1.5% agarose gel and detected by ethidium bromide¯uorescence. Two sets of primers, one for ORF-1 and the other for cellular GAPDH ampli®cation were used (lanes 1 ± 8). The GAPDH and ORF-1 primers amplify 300 and 500 bp products, respectively (lanes 9 and 10). (b) Western blot analysis. In vitro transcribed/ translated products using pET17b/ORF-1 (lane 1) or pET17b (lane 2) as the template, and proteins extracted from infected cells (lanes 3 ± 11) were separated by SDS ± PAGE, transferred to Immobilon-P membrane and immunoblotted employing anti-ORF-1 polyclonal rabbit antibody. Lanes 9 and 10 were from an independent gel. The position of ORF-1 protein is shown on the side of the blot ORF-1 oncoprotein binds to and inhibits p53 F Kashanchi et al speci®city of ORF-1 inhibition of p53-activated transcription. The data suggest that binding of ORF-1 to p53 alters the ability of p53 to regulate cellular genes important in growth control.
Further studies were performed to determine when ORF-1 was expressed in HHV-6 infected cells. Following infection, HSB-2 cells were harvested at selected times. ORF-1 message was detected from 18 to 48 h post-infection (lanes 4 ± 8) using RT ± PCR (Figure 5a ). Primers for the GAPDH gene, used in all reactions as a internal RT ± PCR control, resulted in a 300 bp product (lane 9). No ORF-1 PCR product was seen in non-infected cells at 0 time or in infected cells at 6 and 12 h, while GAPDH PCR product demonstrated the integrity of the RNA for RT ± PCR in those reactions.
Because ORF-1 mRNA was observed in infected cells, protein extracts were Western blotted (after separation by 4 ± 20% PAGE) and probed with anti-ORF-1 serum. ORF-1 protein (approximately 37 kDa) was detected by 18 h post-infection, but was not observed at earlier times or in non-infected cells at 0 time (Figure 5b ). The detection of the ORF-1 protein coincided with the RNA expression detected by RT ± PCR, indicating a coordinated transcription and translation pathway. When preimmune serum was used to probe the same blot, no speci®c *37 kDa band was seen (data not shown). Therefore, ORF-1 protein was readily detected as early as 18 h postinfection. Repeated Western blots have shown similar levels of ORF-1 protein from 18 to 72 h.
The association of the ORF-1 oncogene with human malignancies was investigated. Glioblastomas and pathologic lymph nodes from patients with angioimmunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy-like lymphoma, HD, and both B-and Tcell lineage NHL were examined by PCR for the presence of ORF-1 sequences (Table 1) . ORF-1 sequences were identi®ed at a low frequency in most of the malignancies studied, but they were present in ®ve of 12 lymph nodes of angioimmunoblastic lymphadenopathy. In contrast, all 10 non-malignant lymph nodes and all 10 normal brain tissues examined were negative when tested for ORF-1. Of interest, one of the glioblastomas positive for ORF-1 showed no trace of normal tissue in the sample, demonstrating that this viral sequence was present in the neoplastic cells.
Using Southern blot analysis, the SalI-L fragment containing the ORF-1 sequence was detected in HHV-6 strain GS infected HSB-2 cells and in pathologic lymph nodes of both HD cases found positive by PCR (data not shown). The BamHI/SalI restriction fragment pattern for DNA from the HD cases diered from that of the DNA from HHV-6A infected cells. Other tissues, positive for ORF-1 by PCR, were not examined by Southern blot analysis because insucient DNA was available.
Discussion
HHV-6 infection may be an important co-factor in the pathogenesis of AIDS (Ablashi et al., 1987 Lusso et al., 1988 Lusso et al., , 1995 Takahashi et al., 1989) . Several reports indicate that HHV-6 viral transactivation accelerates the progression of HIV-1 infection in vitro (Horvat et al., 1991; Martin et al., 1991; Thompson et al., 1994; Kashanchi et al., 1994) . Conversely, the HIV-1 transactivator, Tat, increases HHV-6 replication which may lead to destruction of CD4 + T-cells in co-infected individuals (Sieczkowski et al., 1995) . Detection of both HIV-1 and HHV-6 in the same cell in vivo has been demonstrated (Blazquez et al., 1995; Qavi et al., 1995; Saito et al., 1995) , validating the results obtained by co-infection experiments in vitro (Lusso et al., 1989 (Lusso et al., , 1992 .
Our previous characterization of SalI-L revealed its ability to transactivate the HIV-1 LTR promoter in both monkey kidney and human T-cells. Subsequently, the transactivating activity of SalI-L was localized to a 357 aa ORF, designated ORF-1 , which also contains sequences with homology to the common domains of the HCMV US22 family of proteins. Additionally, SalI-L transformed rodent cells were tumorigenic when injected into nude mice. SalI-L was retained in both transformed and tumor derived cells as detected by Southern blot analysis, suggesting its role in tumorigenesis.
In the current investigation, the transforming activity of HHV-6 SalI-L was localized to the SalI-L-SH fragment and ®nally, to ORF-1 (Figure 2) . Moreover, ORF-1 protein expression was retained in the tumor tissue. The co-localization of both transactivating and transforming activities to ORF-1 is the ®rst for HHV-6, but is a characteristic of other viral oncoproteins including SV40 T-antigen, adenovirus E1a, HTLV-1 tax and HPV E6 (Hansen et al., 1995; Tlsty et al., 1994; White, 1995 Co-immunoprecipitation studies showed that ORF-1 protein bound to the p53 tumor suppressor protein (Figure 3) . Studies of ORF-1 binding to p53 truncated proteins demonstrated that ORF-1 bound to the speci®c DNA binding domain of p53. The results indicate that the ORF-1 binding domain of p53 is between residues 28 and 187 with a critical region between 107 and 187. Because the speci®c DNA binding domain of p53 is required for p53-activated transcription, p53 transcription was studied in ORF-1 transformed cells. An eightfold decrease in CAT activity was found in 3T3-ORF1-1 cells after transfection with a p53 responsive reporter construct ( Figure  4 ). This decrease in transcriptional activation was not observed in non-tumorigenic cells expressing the truncated TTL 172 mutant ORF-1 protein. These data suggest that the binding of ORF-1 protein to p53 blocks p53 from binding to DNA and thus, prevents transactivation. The ability of ORF-1 to inhibit p53-activated transcription suggests a possible mechanism for ORF-1 transformation.
Expression of ORF-1 in infected cells was studied to determine when this protein appears in the course of HHV-6 replication. Both ORF-1 mRNA and protein were detected in HHV-6 infected cells by 18 h ( Figure  5 ), indicating that ORF-1 is a viral gene product.
Previous molecular and serologic studies suggested a role for HHV-6 in human cancers. HHV-6 sequences were detected in a number of human malignancies including African Burkitt's lymphoma ), Hodgkin's lymphoma (Torelli et al., 1991) , and Epstein ± Barr-virus-negative B-cell lymphoma , as well as AIDSrelated malignancies (Bovenzi et al., 1993) . HHV-6 antigens were also detected in 77% of Hodgkin's lymphomas (Krueger et al., 1994) . HHV-6 increased the expression of the HPV-18 genome in both tumor cells and immortalized cells . Furthermore, speci®c fragments of HHV-6 DNA transactivated the long control region of HPV-18, an important and clinically high-risk pathogenic agent in cervical cancer (10 ± 20% of cervical carcinomas were HPV-18 positive) .
Because of the reported association of HHV-6 with human malignancies and our identi®cation of the ORF-1 oncogene, human cancers were screened for ORF-1 sequences (Table 1) . ORF-1 DNA sequences were detected by PCR in pathologic lymph nodes from ®ve of 12 patients with angioimmunoblastic lymphadenopathy, but not in 10 control lymph nodes with no malignant histology. Moreover, ORF-1 DNA sequences were observed at lower frequency in pathologic tissues from patients with other cancers such as HD, NHL, and glioblastoma. All ORF-1 positive samples were also positive by PCR for HHV-6 ZVH14 and ZVB70 sequences and all samples except one HD case were positive for HD12 sequences . Furthermore, in all cases the ZVH14 PCR products contained an internal HindIII restriction site characteristic of HHV-6B strains. Southern blot analysis showed that BamHI/SalI digested DNA fragments from HD lymph nodes exhibited polymorphism. While the size pattern of fragments was not that of HHV-6A, it is not known if the polymorphism was characteristic of HHV-6B. However, other restriction fragments of DNA isolated from these HD tissues exhibited HHV-6B polymorphism when probed with ZVH14 (Luppi et al., 1993a) . Taken together, these results suggest that all of the ORF-1 positive malignant tissues contained partial or complete HHV-6B genomes. Thus, ORF-1 sequences, which exhibit oncogenic properties, were retained at variable frequency in various human tumor tissues. These observations, while not proof per se, are a necessary prerequiste for establishing the role of ORF-1 in human tumor development.
In summary, both transactivating and transforming activities have now been localized to HHV-6 ORF-1. The binding of ORF-1 to p53 and inhibition of p53-activated transcription were demonstrated. These activities coupled with the detection of ORF-1 in malignant tissues may indicate a role of ORF-1 in human cancer.
Materials and methods

SalI-L constructs and other plasmids
pBS/SalI-L, pBS/SalI-L-SH, pBS/SalI-L-BN, and pBS/SalI-L-NS have been described . pBS/ SalI-L-SB was constructed by digesting pBS/SalI-L with BamHI and ligating the gel-puri®ed 1.1 kbp fragment into the BamHI site of pBLUESCRIPT SK + (Stratagene). pBS/ SalI-L-BS was constructed by digesting pBS/SalI-L with BamHI and re-ligating the gel-puri®ed 5.8 kbp fragment. pBS/SalI-L-HS was constructed by digesting pBS/SalI-L with HindIII and re-ligating the gel-puri®ed 5.0 kbp fragment. The pBK/ORF1 plasmid was constructed by inserting the XbaI fragment containing ORF-1 from pC6/ ORF-1(S) into the XbaI site of pBK-CMV. The construct pBK/ORF1/TTL 172 contained the translation termination linker, CTAGCTAGCTGA, ligated into the NotI site after aa 172. The pBK/ORF3 and pBK/ ORF7 plasmids were constructed by cloning the same PCR ampli®cation product (containing XbaI termini) in both orientations into the XbaI site of pBK-CMV. pET17b/ORF-1 has been described. Plasmid p53G5BCAT, a p53 responsive reporter construct with the CAT gene driven by a promoter containing two copies of p53 binding sites from the ribosomal gene cluster, was a gift from Dr SJ Kim (NCl, NIH, Bethesda, MD). pCAT-Basic was obtained from Promega. pT7Hup53 containing human p53 cloned in a pT7 vector and its deletion derivatives 3R, 4U, and D11 were gifts from Dr D Lane (Midgley et al., 1992; Nissim et al., 1994) .
Establishment of ORF-1 expressing cell lines
The plasmids pBK-CMV, pBK/ORF1, and pBK/ORF1/ TTL 172 (2 mg of each) were linearized by digestion with the blunt end restriction enzyme ApaLI, which cuts within the pBR322 sequence of pBK-CMV. The linearized DNA was transfected into 2610 5 NIH3T3 cells in a 60 mm dish using Lipofectamine (Gibco BRL) according to the manufacturer's protocol. At 48 h post-transfection, cells were split 1 : 100 into 10 cm dishes and colonies selected in Dulbecco's Modi®ed Eagle's Medium (supplemented with 7% calf serum (Hyclone), penicillin (100 units/ml) and streptomycin (100 mg/ml) containing 500 mg/ml geneticin. Selected cells were maintained as subcon¯uent monolayers in the same medium with 100 mg/ml geneticin.
Tumorigenicity assay
The tumorigenic potential of selected cell lines was tested in nude mice as previously described (Clanton et al., 1983;  ORF-1 oncoprotein binds to and inhibits p53 F Kashanchi et al Thompson et al., 1994) . Brie¯y, 3T3-pBK-1, 3T3-ORF1-1, and 3T3-ORF1/TTL 172 -1 cells were established by transfection with pBK-CMV, pBK/ORF1, and pBK/ORF1/TTL 172 , respectively. Geneticin selected cells (5610 6 /100 ml) were injected into nude mice subcutaneously behind the neck. The mice were monitored every 3 days for the appearance of tumors.
Western blot analysis
HHV-6 infected cells (10 7 ), transfected cells, or tumor tissues were collected, washed twice with PBS, pelleted, resuspended in 100 ml of lysis buer (100 mM Tris, pH 7.4; 300 mM NaCl; 10 mM EDTA; 0.1% Nonidet P40), freezethawed three times on dry ice-ethanol, and centrifuged at 12 000 r.p.m. 100 mg of protein extract were loaded on 4 ± 20% SDS ± PAGE. The proteins were transferred to Immobilon-P and probed with either anti-ORF-1 polyclonal antibody, pre-immune rabbit serum (1 : 1000 dilution), or anti-p53, Ab-1, monoclonal antibody (1.0 mg), as appropriate. The immune complex was detected using 125 I-labeled protein A (Amersham Inc).
Binding assays
All 35 S-labeled proteins were prepared by a coupled in vitro transcription/translation TNT protocol (Promega). For immunoprecipitations, 35 S-labeled proteins (10 ml) were mixed in TNE100 (100 mM Tris, pH 8.0; 100 mM NaCl; 1 mM EDTA; 0.1% NP-40) in a ®nal volume of 200 ml for 1 h at 48C. Anti-ORF-1 antibody (10 ml of polyclonal serum) was mixed with the lysate and rotated for 2 h followed by the addition of protein A beads (20 ml). Immune complexes were collected 1 h later, washed with TNE100 containing 1% Nonidet P40, separated by 4 ± 20% SDS ± PAGE, dried and analysed on a phosphoimager. For binding studies of ORF-1 to truncated p53 proteins, cold ORF-1 protein was used.
To quantitate the percent of input full length or truncated p53 protein that co-immunprecipitated with ORF-1, an aliquot of each input 35 S-methionine labeled p53 protein was analysed by SDS ± PAGE concurrently with the coimmunoprecipitations. The levels of full length or truncated p53 in the appropriate input and co-immunoprecipitated lanes were determined by phosphoimager analysis using Image-Quant Software.
p53-activated transcription
NIH3T3 and 3T3-ORF1-1 cell lines were transfected with p53G5BCAT or pCAT-Basic. After 48 h, cell extracts were prepared by three cycles of freeze thawing followed by centrifugation to remove cell debris. An equal amount of total protein, determined using the BIORAD protein assay kit, was used in each assay. CAT activity was assayed in the presence of 0.125 mCi of 14 C-chloramphenicol (Amersham) and 5 mM acetyl-CoA (Sigma) at 378C for 1 h. Acetylated and non-acetylated forms of chloramphenicol were separated by TLC and quantitated by phosphoimager analysis.
Patient samples
Formalin-®xed and paran-embedded lymph node tissues were obtained from 12 patients with a clinical and histologic diagnosis of angioimmunoblastic lymphadenopathy with dysproteinanemia (AILD) and angioimmunoblastic lymphadenopathy-like lymphoma, from 64 patients with NHL and from 25 patients with HD. Frozen lymph node biopsies were also available from two HD cases. Control tissues included 10 formalin ®xed and paran embedded lymph nodes with non-malignant histology and 10 autopsy normal brain tissues. The latter were obtained within 18 h of death from 10 adult immunocompetent subjects free of clinical signs or records of in¯ammatory or systemic diseases associated with the central nervous system. The control lymph nodes consisted of two groups of tissues: two non-hyperplastic lymph nodes which were obtained during staging lymphadenectomy and were free of tumor; eight hyperplastic lymph nodes which showed histologic changes indicating viral or other infections, such as enrichment of peri-and interfollicular blast cells.
Formalin-®xed and paran-embedded specimens of primary brain tumors of glioblastoma type were obtained from surgical biopsies of 13 patients. Four tumor biopsies showed a variable percentage of normal tissue ranging from 10 to 40% of the whole histologic section, while nine cases revealed no trace of normal tissue adjacent to the neoplastic population, as shown by standard histologic examination.
DNA preparation and PCR analysis for ORF-1 sequences
High-molecular weight DNA was extracted with phenol/ chloroform and precipitated with ethanol. Two single (5 m thick, 0.561 cm 2 ) formalin-®xed and paran-embedded tissue sections were cut from paran blocks using a new blade for each block to avoid cross-contamination. The ®rst of each mirror section was retained for standard histologic staining, while the other was deparanized with xylene, washed with 80% ethanol, resuspended in PCR buer with non-ionic detergents (50 mM KCl; 10 mM TrisHCl, pH 8.3; 2.5 mM MgCl 2 ; 200 ng/ml gelatin; 0.45% Nonidet P40; 0.45% Tween 20), and digested with proteinase K at a ®nal concentration of 1.0 mg/ml for 16 h at 558C (Luppi et al., 1993b . Samples consisting of crude extracts were overlaid with mineral oil and then boiled for 10 min before PCR reaction.
Either 1 mg of each DNA sample or 10 ml aliquots of crude extracts were added to a 100 ml reaction containing 50 pmol of each primer, 2.5 U of Taq polymerase, 200 mM of each deoxynucleotide triphosphate, 10 mM Tris-HCl, 1.5 mM MgCl 2 and 50 mM KCl (pH 8.3). The pair of primers used ampli®ed a 500 base pair segment of ORF-1 Kashanchi et al., 1994) . The nucleotide sequences of the sense and antisense primers were: 5'-ATGCGGCATCTCCC-3' sense, 5'-TCGAACAGATGTCGG-3' antisense. PCR cycles were as follows: cycle 1, 958C for 2 min; cycles 2 to 36, 958C for 1 min, 508C for 2 min, 728C for 2 min; cycle 37, 728C for 2 min. For each PCR test, positive and negative controls consisted of DNA extracted from the HHV-6-infected and noninfected HSB-2 cells, respectively (Ablashi et al., 1987) . Negative controls, consisting of all reagents except sample DNA, were prepared during the crude extract preparation. Their number was equal to or greater than the number of the experimental samples assayed. To avoid false positive results, all procedures were performed exactly according to the recommendations of Kwok and Higuchi (1989) .
Southern blot analysis
DNA samples extracted from the pathologic lymph node biopsies of one NHL patient and one HD patient, as well as from the HHV-6-infected and uninfected HSB-2 cell lines, were digested with BamHI and HindIII and hybridized with the SalI-L fragment of the HHV-6 strain U1102 Kashanchi et al., 1994) .
HHV-6 infection
HSB-2 cells were infected with cell free stocks of HHV-6 strain U1102 as previously described . Brie¯y, viral stocks were obtained ®ve days after infection of HSB-2 cells by harvesting and ®ltering the supernatant. When used at a 1 : 10 dilution, over 90% of HSB-2 cells ORF-1 oncoprotein binds to and inhibits p53 F Kashanchi et al were infected as determined by immunohistochemistry. At each time after infection, cells were centrifuged, washed twice and resuspended in PBS, and separated into equal aliquots for RNA preparation (RNAzol method) and Protein extraction (using the lysis buer: 100 mM Tris, pH 7.5; 100 mM NaCl; 10 mM EDTA; 0.1% Nonidet P40). protein (100 mg) was separated by 4 ± 20% SDS ± PAGE and Western blotted with either anti-ORF-1 polyclonal rabbit serum or preimmune serum. RT ± PCR was performed as described (Kashanchi et al., 1993) employing the ORF-1 PCR primers speci®ed above and GAPDH primers (Ko et al., 1995) to amplify cellular GAPDH mRNA. Ampli®cation of the latter serves as an internal RT ± PCR control to demonstrate the integrity of the RNA used for the reactions.
